Skip to Content

Supernus Pharmaceuticals Inc SUPN

Morningstar Rating
$33.63 −0.15 (0.44%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SUPN is trading at a 24% discount.
Price
$32.83
Fair Value
$15.59
Uncertainty
High
1-Star Price
$46.87
5-Star Price
$78.87
Economic Moat
Shnlv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SUPN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$33.78
Day Range
$33.4634.08
52-Week Range
$22.0739.09
Bid/Ask
$33.60 / $33.72
Market Cap
$1.84 Bil
Volume/Avg
116,156 / 400,840

Key Statistics

Price/Earnings (Normalized)
125.48
Price/Sales
3.08
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
652

Comparables

Valuation

Metric
SUPN
ITCI
NEU
Price/Earnings (Normalized)
125.4817.17
Price/Book Value
2.0011.3613.41
Price/Sales
3.0814.4611.97
Price/Cash Flow
15.5815.01
Price/Earnings
SUPN
ITCI
NEU

Financial Strength

Metric
SUPN
ITCI
NEU
Quick Ratio
1.384.955.68
Current Ratio
1.705.415.78
Interest Coverage
−2.18
Quick Ratio
SUPN
ITCI
NEU

Profitability

Metric
SUPN
ITCI
NEU
Return on Assets (Normalized)
2.53%−13.47%122.78%
Return on Equity (Normalized)
4.09%−15.88%141.09%
Return on Invested Capital (Normalized)
2.73%−17.96%137.22%
Return on Assets
SUPN
ITCI
NEU
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class APhnqdytjgVcm$77.2 Bil
MKKGY
Merck KGaA ADRMcxgggfxBdcws$75.4 Bil
HLN
Haleon PLC ADRYywfqbvrzXzx$38.1 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRDnnlwdmztWtzj$16.0 Bil
VTRS
Viatris IncBtqtpjkGnsj$14.0 Bil
RDY
Dr Reddy's Laboratories Ltd ADRQngjxlrbJsqg$12.1 Bil
CTLT
Catalent IncCmmnmwsZspvfgv$10.2 Bil
PRGO
Perrigo Co PLCCrkzmpgrWsv$4.3 Bil
CURLF
Curaleaf Holdings IncDshqlpqbXzkj$4.0 Bil
PBH
Prestige Consumer Healthcare IncCswwfccZhnft$3.6 Bil

Sponsor Center